Does the media prefer IBIO or RNAC?

In the previous week, Cartesian Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.66 beat Cartesian Therapeutics' score of 0.63 indicating that iBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCYC or IBIO more profitable?

iBio has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics -344.95% -35.74% -29.54% iBio N/A -53.86% -46.48%

Does the media favor BCYC or IBIO?

In the previous week, Bicycle Therapeutics had 9 more articles in the media than iBio. MarketBeat recorded 11 mentions for Bicycle Therapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.66 beat Bicycle Therapeutics' score of -0.29 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IBIO or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Galectin Therapeutics N/A N/A -164.69%

Does the media refer more to IBIO or GALT?

In the previous week, Galectin Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Galectin Therapeutics and 2 mentions for iBio. Galectin Therapeutics' average media sentiment score of 0.93 beat iBio's score of 0.66 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, IBIO or MGNX?

iBio has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 180.09 -$18.38M -$0.58 N/A MacroGenics $149.50M 1.91 -$74.62M -$1.10 N/A

Is IBIO or MGNX more profitable?

iBio has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. iBio's return on equity of -53.86% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% MacroGenics -44.79% -147.80% -28.40%

Does the media refer more to IBIO or MGNX?

In the previous week, MacroGenics had 2 more articles in the media than iBio. MarketBeat recorded 4 mentions for MacroGenics and 2 mentions for iBio. MacroGenics' average media sentiment score of 0.91 beat iBio's score of 0.66 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IBIO or NMRA more profitable?

iBio's return on equity of -53.86% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Neumora Therapeutics N/A -181.70% -119.15%

Does the media refer more to IBIO or NMRA?

In the previous week, Neumora Therapeutics had 3 more articles in the media than iBio. MarketBeat recorded 5 mentions for Neumora Therapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.66 beat Neumora Therapeutics' score of 0.52 indicating that iBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

iBio (IBIO) Competitors

$1.45 -0.06 (-3.97%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$1.50 +0.05 (+3.79%)

As of 04:39 AM Eastern

Compare

IBIO vs. RNAC, BCYC, GALT, MGNX, and NMRA

Should you buy iBio stock or one of its competitors? MarketBeat compares iBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iBio include Cartesian Therapeutics (RNAC), Bicycle Therapeutics (BCYC), Galectin Therapeutics (GALT), MacroGenics (MGNX), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry.

How does iBio compare to Cartesian Therapeutics?

iBio (NASDAQ:IBIO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

7.9% of iBio shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

iBio presently has a consensus target price of $5.00, suggesting a potential upside of 244.83%. Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 277.75%. Given Cartesian Therapeutics' higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

iBio has higher earnings, but lower revenue than Cartesian Therapeutics. iBio is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	180.09	-$18.38M	-$0.58	N/A
Cartesian Therapeutics	$2.80M	90.55	-$130.30M	-$5.90	N/A

iBio has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

iBio has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, Cartesian Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.66 beat Cartesian Therapeutics' score of 0.63 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cartesian Therapeutics beats iBio on 9 of the 17 factors compared between the two stocks.

How does iBio compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

iBio has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
iBio	N/A	-53.86%	-46.48%

Bicycle Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 221.84%. iBio has a consensus target price of $5.00, suggesting a potential upside of 244.83%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Bicycle Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, iBio has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Bicycle Therapeutics had 9 more articles in the media than iBio. MarketBeat recorded 11 mentions for Bicycle Therapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.66 beat Bicycle Therapeutics' score of -0.29 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has lower revenue, but higher earnings than Bicycle Therapeutics. iBio is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.17	-$218.96M	-$3.15	N/A
iBio	$400K	180.09	-$18.38M	-$0.58	N/A

Summary

Bicycle Therapeutics beats iBio on 9 of the 17 factors compared between the two stocks.

How does iBio compare to Galectin Therapeutics?

iBio (NASDAQ:IBIO) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

7.9% of iBio shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

iBio presently has a consensus price target of $5.00, suggesting a potential upside of 244.83%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 139.13%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics' return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Galectin Therapeutics	N/A	N/A	-164.69%

iBio has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, Galectin Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Galectin Therapeutics and 2 mentions for iBio. Galectin Therapeutics' average media sentiment score of 0.93 beat iBio's score of 0.66 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	180.09	-$18.38M	-$0.58	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

Summary

iBio beats Galectin Therapeutics on 9 of the 15 factors compared between the two stocks.

How does iBio compare to MacroGenics?

iBio (NASDAQ:IBIO) and MacroGenics (NASDAQ:MGNX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

iBio currently has a consensus target price of $5.00, indicating a potential upside of 244.83%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 22.22%. Given iBio's stronger consensus rating and higher probable upside, research analysts clearly believe iBio is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

iBio has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

iBio has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. iBio's return on equity of -53.86% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
MacroGenics	-44.79%	-147.80%	-28.40%

In the previous week, MacroGenics had 2 more articles in the media than iBio. MarketBeat recorded 4 mentions for MacroGenics and 2 mentions for iBio. MacroGenics' average media sentiment score of 0.91 beat iBio's score of 0.66 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	180.09	-$18.38M	-$0.58	N/A
MacroGenics	$149.50M	1.91	-$74.62M	-$1.10	N/A

7.9% of iBio shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

iBio beats MacroGenics on 11 of the 17 factors compared between the two stocks.

How does iBio compare to Neumora Therapeutics?

iBio (NASDAQ:IBIO) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

iBio currently has a consensus target price of $5.00, indicating a potential upside of 244.83%. Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 310.71%. Given Neumora Therapeutics' higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

7.9% of iBio shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Neumora Therapeutics had 3 more articles in the media than iBio. MarketBeat recorded 5 mentions for Neumora Therapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.66 beat Neumora Therapeutics' score of 0.52 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market.

iBio has higher revenue and earnings than Neumora Therapeutics. iBio is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	180.09	-$18.38M	-$0.58	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

iBio's return on equity of -53.86% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Summary

iBio beats Neumora Therapeutics on 8 of the 15 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$75.01M	$931.69M	$5.06B	$12.61B
Dividend Yield	N/A	4.84%	27.48%	8.00%
P/E Ratio	-2.50	1.56	23.70	24.26
Price / Sales	180.09	114.76	146.11	117.88
Price / Cash	N/A	22.05	31.98	49.36
Price / Book	1.61	8.59	12.23	6.29
Net Income	-$18.38M	-$3.66M	$118.20M	$330.66M
7 Day Performance	-8.81%	-2.06%	-1.63%	-1.35%
1 Month Performance	-14.20%	0.77%	-1.93%	-0.64%
1 Year Performance	N/A	37.84%	8.97%	19.08%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	2.7013 of 5 stars	$1.45 -4.0%	$5.00 +244.8%	N/A	$75.01M	$400K	N/A	100	Analyst Downgrade
RNAC Cartesian Therapeutics	3.076 of 5 stars	$10.25 +2.0%	$32.60 +218.0%	-35.2%	$301.17M	$1.78M	N/A	64	Gap Down
BCYC Bicycle Therapeutics	2.6196 of 5 stars	$4.28 -2.3%	$14.00 +227.1%	-45.6%	$298.79M	$63.50M	N/A	240	News Coverage
GALT Galectin Therapeutics	1.9542 of 5 stars	$4.51 -2.2%	$11.00 +143.9%	+83.3%	$297.03M	N/A	N/A	9
MGNX MacroGenics	2.4267 of 5 stars	$4.66 -1.9%	$5.50 +18.0%	+179.5%	$296.19M	$149.50M	N/A	430

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. RNAC, BCYC, GALT, MGNX, and NMRA

How does iBio compare to Cartesian Therapeutics?

Summary

How does iBio compare to Bicycle Therapeutics?

Summary

How does iBio compare to Galectin Therapeutics?

Summary

How does iBio compare to MacroGenics?

Summary

How does iBio compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. RNAC, BCYC, GALT, MGNX, and NMRA

How does iBio compare to Cartesian Therapeutics?

Do insiders and institutionals hold more shares of IBIO or RNAC?

Do analysts recommend IBIO or RNAC?

Which has stronger valuation and earnings, IBIO or RNAC?

Is IBIO or RNAC more profitable?

Which has more risk and volatility, IBIO or RNAC?

Does the media prefer IBIO or RNAC?

Summary

How does iBio compare to Bicycle Therapeutics?

Is BCYC or IBIO more profitable?

Do analysts rate BCYC or IBIO?

Which has more volatility & risk, BCYC or IBIO?

Do institutionals and insiders hold more shares of BCYC or IBIO?

Does the media favor BCYC or IBIO?

Which has preferable valuation & earnings, BCYC or IBIO?

Summary

How does iBio compare to Galectin Therapeutics?

Do insiders and institutionals hold more shares of IBIO or GALT?

Do analysts recommend IBIO or GALT?

Is IBIO or GALT more profitable?

Which has more risk and volatility, IBIO or GALT?

Does the media refer more to IBIO or GALT?

Which has higher earnings & valuation, IBIO or GALT?

Summary

How does iBio compare to MacroGenics?

Do analysts prefer IBIO or MGNX?

Which has more volatility and risk, IBIO or MGNX?

Is IBIO or MGNX more profitable?

Does the media refer more to IBIO or MGNX?

Which has stronger valuation & earnings, IBIO or MGNX?

Do insiders & institutionals believe in IBIO or MGNX?

Summary

How does iBio compare to Neumora Therapeutics?

Do analysts recommend IBIO or NMRA?

Do institutionals & insiders believe in IBIO or NMRA?

Does the media refer more to IBIO or NMRA?

Which has more volatility and risk, IBIO or NMRA?

Which has preferable valuation and earnings, IBIO or NMRA?

Is IBIO or NMRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools